Department of Systems Medicine, Gastroenterology Unit, University 'Tor Vergata' of Rome, Italy.
Eur J Gastroenterol Hepatol. 2023 Sep 1;35(9):948-954. doi: 10.1097/MEG.0000000000002554. Epub 2023 Jul 17.
The long-term outcome of inflammatory bowel disease (IBD) patients after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is under investigation.
To assess, in a prospective study, whether a recent SARS-CoV-2 infection increases the risk of IBD relapse within 12 months.
From March to April 2021, all IBD patients with recent (<2 months) SARS-CoV-2 infection (Cases) were enrolled. For each enrolled Case, four IBD Controls with no history of infection were considered. Clinical course of IBD was recorded for 12 months. Inclusion criteria: well defined diagnosis of IBD; age ≥18 and ≤85 years; 12-month follow-up; consent. Exclusion criteria: incomplete data; SARS-CoV-2 infection after enrollment. Additional inclusion criteria: recent SARS-CoV-2 infection for Cases; no history of SARS-CoV-2 infection for Controls. Data expressed as median [range]. Statistical analysis: Student-t-Test, Mann-Whitney U-test, χ2 test, multivariate logistic regression model [odds ratio (95% confidence interval)], Kaplan-Meier curves.
One hundred forty-three IBD patients were enrolled. The analysis included 118 patients (22 met the exclusion criteria, three lost at follow-up): 29 (24.6%) Cases and 89 (75.4%) Controls. Demographic and clinical characteristics were comparable between groups. During the 12-month study, the frequency of IBD relapse was comparable between Cases and Controls [8 (27%) vs 19 (21%); P = 0.65]. At univariate analysis, SARS-CoV-2 infection was not a risk factor for IBD relapse within 12 months [1.5 (0.6-3.9); P = 0.34]. At multivariate analysis, IBD activity at baseline was the only risk factor for relapse [3.2 (1.1-9.1); P = 0.03]. Kaplan-Meier curves showed that survival from IBD relapse was comparable between Cases and Controls (P = 0.33).
In a prospective 12-month study, a recent SARS-CoV-2 infection did not increase the risk of clinical relapse of IBD in the long term.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染后炎症性肠病（IBD）患者的长期预后仍在研究中。
前瞻性研究评估近期 SARS-CoV-2 感染是否会增加 12 个月内 IBD 复发的风险。
2021 年 3 月至 4 月，纳入所有近期（<2 个月）SARS-CoV-2 感染的 IBD 患者（病例）。对每例入组的病例，均纳入 4 例无感染史的 IBD 对照。12 个月时记录 IBD 临床病程。纳入标准：IBD 明确诊断；年龄≥18 岁且≤85 岁；随访 12 个月；同意。排除标准：数据不完整；入组后 SARS-CoV-2 感染。额外纳入标准：病例有近期 SARS-CoV-2 感染；对照无 SARS-CoV-2 感染史。数据表示为中位数[范围]。统计分析：Student-t-检验、Mann-Whitney U 检验、χ2 检验、多变量逻辑回归模型[比值比（95%置信区间）]、Kaplan-Meier 曲线。
纳入 143 例 IBD 患者。118 例患者纳入分析（22 例因排除标准而排除，3 例失访）：29 例（24.6%）病例和 89 例（75.4%）对照。两组的人口统计学和临床特征相似。在 12 个月的研究期间，病例和对照的 IBD 复发频率相似[8（27%）与 19（21%）；P=0.65]。单因素分析显示，SARS-CoV-2 感染不是 12 个月内 IBD 复发的危险因素[1.5（0.6-3.9）；P=0.34]。多因素分析显示，基线时的 IBD 活动是复发的唯一危险因素[3.2（1.1-9.1）；P=0.03]。Kaplan-Meier 曲线显示，病例和对照的 IBD 复发后生存率无差异（P=0.33）。
在一项前瞻性 12 个月研究中，近期 SARS-CoV-2 感染不会增加 IBD 长期临床复发的风险。
